Medications for benign prostatic hyperplasia
Pro Research Analysisby 
Searched over 200M research papers
Current Medications for Benign Prostatic Hyperplasia (BPH)
Benign prostatic hyperplasia (BPH) is a common condition in aging men, often leading to lower urinary tract symptoms (LUTS) that can significantly affect quality of life. The main classes of medications currently used to treat BPH are alpha-1 adrenergic antagonists (alpha blockers), 5-alpha reductase inhibitors (5-ARIs), and, more recently, phosphodiesterase-5 inhibitors (PDE5Is) and beta-3 adrenoceptor agonists. Combination therapies are also widely used to improve outcomes and reduce the risk of disease progression 2456+2 MORE.
Alpha-1 Adrenergic Antagonists (Alpha Blockers)
Alpha blockers, such as terazosin, tamsulosin, and others, work by relaxing the smooth muscle in the prostate and bladder neck, which helps relieve urinary symptoms quickly. They are considered the first-line treatment for many patients due to their rapid onset of action and effectiveness in improving LUTS 2567+1 MORE.
5-Alpha Reductase Inhibitors (5-ARIs)
5-ARIs, including finasteride and dutasteride, reduce the size of the prostate by blocking the conversion of testosterone to dihydrotestosterone, the hormone responsible for prostate growth. These drugs are particularly effective in men with larger prostates and help prevent disease progression, but they may take several months to show benefits 2567+1 MORE.
Combination Therapy
Combining an alpha blocker with a 5-ARI is often recommended for men with significantly enlarged prostates and more severe symptoms. This approach provides both rapid symptom relief and long-term reduction in prostate size, lowering the risk of acute urinary retention and the need for surgery 57.
Phosphodiesterase-5 Inhibitors (PDE5Is)
PDE5Is, such as tadalafil, are sometimes used, especially in men who have both BPH and erectile dysfunction. These medications can improve urinary symptoms and sexual function, and may be combined with alpha blockers for added benefit 4578.
Beta-3 Adrenoceptor Agonists and Anticholinergics
Beta-3 agonists (e.g., mirabegron) and muscarinic receptor antagonists (MRAs) are used to manage persistent storage symptoms (such as urgency and frequency) that are not fully controlled by other medications. Beta-3 agonists may offer similar efficacy to anticholinergics but with fewer side effects 578.
Plant Extracts and Phytotherapy
Plant-based therapies, such as saw palmetto and Pygeum africanum, are widely used, especially in Europe. However, large, well-designed studies have not shown significant benefits over placebo, though these agents are generally safe. They may be considered for men with mild symptoms who prefer alternative treatments, but are not recommended for moderate or severe BPH 169.
Emerging and Investigational Therapies for BPH
Research is ongoing into new medications and novel targets for BPH treatment. These include:
- Drugs targeting the nitric oxide/cGMP pathway
- OnabotulinumtoxinA (botulinum toxin)
- Vitamin D3 analogues
- Selective cannabinoid receptor agonists
- Talaporfin sodium (a photodynamic therapy agent)
- Inhibitors of transforming growth factor beta 1 (TGF-β1)
- Hormonal therapies beyond traditional 5-ARIs
- Gene therapy and other molecular approaches
These investigational agents aim to provide more personalized and effective treatment options with fewer side effects, but most are still in clinical trials and not yet widely available 1346+1 MORE.
Side Effects and Considerations
While most BPH medications are effective and generally well tolerated, they can cause side effects. Alpha blockers may cause dizziness and low blood pressure; 5-ARIs can lead to sexual dysfunction; PDE5Is may cause headache and flushing; and anticholinergics can result in dry mouth and constipation. Understanding these risks is important for shared decision-making between patients and clinicians 78.
Conclusion
The mainstay of BPH treatment remains alpha blockers, 5-ARIs, and their combination, with PDE5Is and beta-3 agonists as additional options for specific symptoms. Plant extracts are not recommended for moderate or severe cases. Ongoing research into new drug classes and personalized approaches promises to further improve outcomes for men with BPH in the future 1345+5 MORE.
Sources and full results
Most relevant research papers on this topic